Related Experiment Video
Updated: Mar 27, 2026
07:38
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
908
Levetiracetam-induced pancytopenia.
Talal Alzahrani1, Dana Kay2, Saeed A Alqahtani3
1Department of Internal Medicine, George Washington University, Washington DC, USA; Department of Internal Medicine, Taibah University, Medina, KSA.
Epilepsy & Behavior Case Reports
|January 9, 2016
Summary
Levetiracetam (LEV), an anti-seizure medication, can rarely cause pancytopenia, a serious condition requiring hospitalization. Discontinuing LEV successfully treated a patient with this rare side effect.
Area of Science:
- Neurology
- Hematology
- Pharmacology
Background:
- Pancytopenia is a rare but severe adverse effect of levetiracetam (LEV).
- This condition can lead to significant morbidity and necessitate hospitalization.
- Levetiracetam is commonly prescribed for seizure prophylaxis in neurosurgical patients.
Purpose of the Study:
- To report a case of levetiracetam-induced pancytopenia.
- To highlight the importance of recognizing this rare side effect.
- To emphasize the successful management through medication discontinuation.
Main Methods:
- A case report detailing a patient with a right temporoparietal tumor.
- The patient received levetiracetam for seizure prophylaxis post-craniotomy.
- Monitoring for adverse effects, including hematological parameters.
Main Results:
- The patient developed pancytopenia after initiating levetiracetam.
- The condition was successfully managed by discontinuing levetiracetam.
- No further hematological complications were reported after discontinuation.
Conclusions:
- Levetiracetam can induce pancytopenia, a rare but serious complication.
- Early recognition and discontinuation of levetiracetam are crucial for management.
- Increased clinical awareness of LEV-induced pancytopenia is warranted.
Related Concept Videos
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
1.1K
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.1K
01:11Renal Failure: Dose Adjustments
574
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
574
01:20Antiepileptic Drugs: Potassium Channel Activators
949
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
949
01:16Drug toxicity: Idiosyncratic Reactions
165
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
165
01:24Drug Toxicity: Dose-Dependent Reactions
158
Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...
158
01:24Drug Toxicity: Risk factors
167
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
167